Oppenheimer & Co. Inc. Sells 5,144 Shares of Moderna, Inc. (NASDAQ:MRNA)

Oppenheimer & Co. Inc. lowered its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 12.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 37,787 shares of the company’s stock after selling 5,144 shares during the period. Oppenheimer & Co. Inc.’s holdings in Moderna were worth $2,525,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Ashton Thomas Private Wealth LLC bought a new position in shares of Moderna in the second quarter valued at $26,000. Family Firm Inc. bought a new position in Moderna in the 2nd quarter valued at about $33,000. Cedar Wealth Management LLC boosted its stake in Moderna by 45.0% during the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock valued at $31,000 after purchasing an additional 90 shares during the last quarter. Bank & Trust Co bought a new stake in Moderna during the 2nd quarter worth approximately $36,000. Finally, Hanseatic Management Services Inc. purchased a new stake in shares of Moderna in the second quarter worth approximately $48,000. Institutional investors own 75.33% of the company’s stock.

Moderna Stock Down 7.3 %

MRNA opened at $36.85 on Friday. Moderna, Inc. has a 12 month low of $35.80 and a 12 month high of $170.47. The company has a market cap of $14.18 billion, a PE ratio of -6.33 and a beta of 1.69. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. The company has a 50 day moving average of $58.56 and a 200 day moving average of $96.88.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, topping analysts’ consensus estimates of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The firm had revenue of $1.90 billion during the quarter, compared to analyst estimates of $1.25 billion. During the same period last year, the company earned ($1.39) earnings per share. The business’s revenue for the quarter was up 3.8% on a year-over-year basis. On average, sell-side analysts expect that Moderna, Inc. will post -9.43 EPS for the current year.

Insider Buying and Selling at Moderna

In other Moderna news, CFO James M. Mock sold 1,321 shares of the stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total value of $104,874.19. Following the sale, the chief financial officer now directly owns 8,600 shares in the company, valued at $682,754. This represents a 13.32 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders sold 2,930 shares of company stock valued at $217,170 in the last quarter. 15.70% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the company. Leerink Partners cut their target price on Moderna from $60.00 to $48.00 and set an “underperform” rating on the stock in a research report on Tuesday, September 17th. Deutsche Bank Aktiengesellschaft upgraded shares of Moderna from a “sell” rating to a “hold” rating and reduced their target price for the stock from $85.00 to $80.00 in a research note on Wednesday, August 7th. Sanford C. Bernstein started coverage on shares of Moderna in a research report on Thursday, October 17th. They set a “market perform” rating and a $55.00 price target on the stock. Royal Bank of Canada reiterated a “sector perform” rating and issued a $75.00 price objective on shares of Moderna in a research note on Thursday, September 19th. Finally, Wolfe Research initiated coverage on Moderna in a research note on Friday. They issued an “underperform” rating and a $40.00 target price on the stock. Three equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Moderna has an average rating of “Hold” and a consensus target price of $90.22.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.